Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa

PURPOSE: In a randomized phase III trial, sunitinib was associated with significantly superior progression-free survival (PFS) when compared with interferon alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma. We investigated whether baseline quality-of-life (QOL) and...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Cella, David, Cappelleri, Joseph C., Bushmakin, Andrew, Charbonneau, Claudie, Li, Jim Z., Kim, Sindy T., Chen, Isan, Michaelson, M. Dror, Motzer, Robert J.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2009
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2790652/
https://ncbi.nlm.nih.gov/pubmed/20856722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.0922004
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы